Jennifer Fox
Director/Board Member bei PROKIDNEY CORP.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Jennifer Fox is currently the Director at Life Science Cares, Inc. She also holds current positions as an Independent Director at ProKidney Corp., Apogee Therapeutics, Inc., and Zenas Pharma, Inc. In the past, Jennifer worked as a Managing Director at Deutsche Bank AG, New York Branch from 2006 to 2015.
She also served as a Director at the Elizabeth Glaser Pediatric AIDS Foundation and as a Senior MD-Healthcare Investment Banking at Bear, Stearns & Co., Inc. Jennifer was a Vice President-Healthcare Investment Banking at Bank of America Corp.
and later became MD & Co-Head-North America Healthcare at Citigroup, Inc. from 2015 to 2020.
She also held positions at Prudential Vector Healthcare Group and Prudential Securities, Inc. (Michigan) as a Vice President-Health Care Investment Banking.
From 2020 to 2023, Jennifer was the Chief Financial Officer & Secretary at Nuvation Bio, Inc. Ms. Fox completed her undergraduate degree at Manhattan College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.07.2023 | 34 824 ( 0,08% ) | 2 Mio $ | 31.03.2024 | |
PROKIDNEY CORP. CLASS A
0,07% | 22.05.2023 | 43 123 ( 0,07% ) | 70 722 $ | 31.03.2024 |
| 17.03.2023 | 4 481 ( 0,00% ) | 16 311 $ | 31.03.2024 |
Aktive Positionen von Jennifer Fox
| Unternehmen | Position | Beginn |
|---|---|---|
| PROKIDNEY CORP. | Director/Board Member | 11.07.2022 |
| APOGEE THERAPEUTICS, INC. | Director/Board Member | 22.06.2023 |
| Life Science Cares, Inc. | Director/Board Member | - |
Zenas Pharma, Inc.
 Zenas Pharma, Inc. BiotechnologyHealth Technology Zenas Pharma, Inc. is an American pharmaceutical company that is focused on developing a portfolio of first- and autoimmune therapeutics to address areas of high unmet medical need. The company is located in the US. The company's lead product candidate, obexelimab (zb012), is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. | Director of Finance/CFO | 01.12.2023 |
Ehemalige bekannte Positionen von Jennifer Fox
| Unternehmen | Position | Ende |
|---|---|---|
| NUVATION BIO INC. | Director of Finance/CFO | 27.11.2023 |
| CITIGROUP INC. | Corporate Officer/Principal | 01.10.2020 |
Deutsche Bank AG, New York Branch
 Deutsche Bank AG, New York Branch Regional BanksFinance Deutsche Bank AG provides financial and banking services. It also offers commercial and investment banking services. The company is headquartered in New York, NY. | Corporate Officer/Principal | 01.06.2015 |
Prudential Securities, Inc. (Michigan)
 Prudential Securities, Inc. (Michigan) Investment Banks/BrokersFinance Part of Prudential Financial, Inc., Prudential Securities, Inc. (Michigan) is a private company based in West Bloomfield, MI. | Corporate Officer/Principal | - |
| Prudential Vector Healthcare Group | Corporate Officer/Principal | - |
Ausbildung von Jennifer Fox
| Manhattan College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| CITIGROUP INC. | Finance |
| NUVATION BIO INC. | Health Technology |
| PROKIDNEY CORP. | Health Technology |
| APOGEE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Bear, Stearns & Co., Inc.
 Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information. | Finance |
Deutsche Bank AG, New York Branch
Deutsche Bank AG, New York Branch Regional BanksFinance Deutsche Bank AG provides financial and banking services. It also offers commercial and investment banking services. The company is headquartered in New York, NY. | Finance |
Elizabeth Glaser Pediatric AIDS Foundation
 Elizabeth Glaser Pediatric AIDS Foundation Miscellaneous Commercial ServicesCommercial Services Elizabeth Glaser Pediatric AIDS Foundation engages in preventing pediatric Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS). The company was founded by Susie Zeegen in 1988 and is headquartered in Washington, DC. | Commercial Services |
| Prudential Vector Healthcare Group | Finance |
Prudential Securities, Inc. (Michigan)
Prudential Securities, Inc. (Michigan) Investment Banks/BrokersFinance Part of Prudential Financial, Inc., Prudential Securities, Inc. (Michigan) is a private company based in West Bloomfield, MI. | Finance |
| Life Science Cares, Inc. | |
Zenas Pharma, Inc.
Zenas Pharma, Inc. BiotechnologyHealth Technology Zenas Pharma, Inc. is an American pharmaceutical company that is focused on developing a portfolio of first- and autoimmune therapeutics to address areas of high unmet medical need. The company is located in the US. The company's lead product candidate, obexelimab (zb012), is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. | Health Technology |
